一段话概述
Prime Medicine was created to turn prime editing — the search-and-replace technique — into medicines. Its first therapy, for a rare immune disease, became the first prime-editing treatment given to patients, with results published showing the corrected cells took hold and restored the missing immune function.
Prime Medicine was founded in 2019 by David Liu, Andrew Anzalone and Keith Gottesdiener to develop prime editing therapeutics. PM359, correcting the NCF1 delGT mutation in p47phox-deficient chronic granulomatous disease, produced the first published first-in-human prime-editing results in the New England Journal of Medicine. The company has also pursued liver programmes including Wilson's disease.
Sources
- New England Journal of Medicine · 2025
Prime Editing for p47phox-Deficient Chronic Granulomatous Disease ↗
非投资建议
本档案为依据公开披露信息汇编的教育性资料，不构成对任何证券的买入、卖出或持有建议，也不代表对该公司前景的任何判断。生物技术领域具有高度投机性，大多数临床项目最终以失败告终。
完整免责声明 →